Metformin in Kidney Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

125

Participants

Timeline

Start Date

October 1, 2014

Primary Completion Date

December 31, 2019

Study Completion Date

December 31, 2019

Conditions
Chronic Kidney DiseaseCardiovascular DiseaseMetabolic Syndrome
Interventions
DRUG

metformin

500 to 1500 mg orally per day for 16 weeks if eGFR \> 45 ml/min; 500 to 1000 mg orally per day for 16 weeks if eGFR =\< 45 ml/min

DRUG

Placebo

placebo pill(s) orally per day for 16 weeks

Trial Locations (1)

37212-2637

Tennessee Valley Healthcare System Nashville Campus, Nashville, TN, Nashville

All Listed Sponsors
lead

VA Office of Research and Development

FED

NCT02252081 - Metformin in Kidney Disease | Biotech Hunter | Biotech Hunter